CXCL13 and myeloid sarcoma: Columba-Cabezas et al. were able to suppress ELFs and CNS CXCL13 production in EAE using a lymphotoxin beta receptor-Ig fusion protein, and they proposed that this approach might be able to be used for the treatment of MS [27].